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Review question/objective 
The objective of this review is to identify the effectiveness of education or behavioral interventions on 
adherence to phosphate control in adults with end stage kidney disease (ESKD) receiving 
hemodialysis (HD). 
Background 
Hyperphosphatemia occurs in people with ESKD as a result of the kidneys’ reduced ability to excrete 
an ingested phosphate load.
1,2
 Hyperphosphatemia significantly lowers the serum calcium 
concentration, stimulating the release of parathyroid hormone (PTH), causing secondary 
hyperparathyroidism.
3-6
 In ESKD, hyperphosphatemia also slows the activation of vitamin D which 
leads to impaired absorption of calcium from the gastrointestinal tract, resulting in reduced 
mobilization of calcium and phosphate from the bones, and causing metabolic bone disease.
2,6,7
 The 
reduced mobilization of both phosphate and calcium enables these two minerals to bind together 
creating a calcium-phosphate product. At a serum concentration of >1.78mmol/L the calcium-
phosphate product crystallizes and is deposited within the soft tissue and vasculature.
6,8,9
 In ESKD 
the development of vascular calcification of the arterial media (i.e. calciphylaxis) is a major 
contributing factor of morbidity and mortality.
4,5,9,10
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Methods of phosphate control  
Hyperphosphatemia is a wellrecognized risk factor for renal osteodystrophy and cardiovascular 
mortality in people with ESKD.
1,4,11
 Collectively this is called chronic kidney disease – mineral bone 
disorder (CKD-MBD). Treatment of hyperphosphatemia requires a combination of dietary phosphate 
restrictions, use of oral phosphate binder therapy to reduce intestinal phosphate absorption, vitamin 
D3 (calcitriol) supplementation and adequate dialysis prescription to promote removal of phosphate.
12-
15
 The treatment goal is to maintain serum phosphate levels at near normal, 0.7 – 1.6mmol/L (3.5 – 
5.5 mg/dL)
16
, and that sustained control of serum phosphate is a strong predictor of improved survival 
in people receiving HD.
11
 However approximately 40% of patients receiving HD have a serum 
phosphate level of >1.6mmol/L.
16
  
Dietary phosphate restriction 
The implementation of dietary phosphate restrictions is the first step in treating hyperphosphatemia. 
The average daily adult diet contains approximately 800-1500mg of phosphate which is absorbed 
mostly in the duodenum and jejunum.
17
 However, there is a linear relationship between phosphate 
and protein intake.
1
 In general, foods high in phosphate such as milk and meat are rich in protein. For 
each gram of protein, there is approximately 13-15mg of phosphate.
17
 The recommended protein 
intake for a HD patient is 0.8g per kg of body weight per day.
7,18
 However, the dietary restrictions 
necessary to sustain acceptable serum phosphate in HD patients could lead to protein 
malnutrition.
4,7,19
 Therefore, dietary phosphate restriction is not sufficient to control serum phosphate 
levels to current national/international guidelines.
19
 
Phosphate binders 
The mainstay treatment of hyperphosphatemia is the use of oral phosphate binder medication.
1,20
 
Phosphate binders lower phosphate absorption in the intestines by binding to and sequestering 
phosphate in the gastrointestinal tract, forming insoluble products that are not readily absorbed.
21
 The 
Dialysis Outcomes and Practice Patterns Study (DOPPS) involving 23,898 patients on HD at 923 
facilities in 12 countries found that 88% of patients were prescribed phosphate binders and 12% were 
not. This study found a 25% lower mortality rate (HR, 0.75; 95% CI, 0.68-0.83) in patients who were 
prescribed phosphate binders versus those not prescribed phosphate binder medication.
11
 However, 
most people receiving phosphate binding medication do not achieve target serum phosphate level.
3
 
Hemodialysis 
The basic conventional four-hour thrice-weekly HD removes approximately 700-1,000mg of 
phosphate per session, resulting in a weekly reduction of 2100-3000mg.
8,21,22
  Effective phosphate 
removal through HD is complicated by phosphate’s biphasic elimination from the body. Kinetic studies 
have shown that serum phosphate levels drop rapidly in the first one to two hours of HD treatment 
and then reach a plateau.
8,22
 Soon after HD, a rebound of serum phosphate occurs to a rise of about 
30–40%. This is because of the slow influx of elements to the extracellular space after a standard HD 
session.
3,8,22
 It has been recognized that increasing dialysis frequency or duration leads to reduced 
serum phosphate.
19
 Data from the Frequent Haemodialysis Network nocturnal trial showed that daily 
or extended nocturnal HD led to an average decrease in serum phosphate levels of 0.4mmol/L (95% 
CI: 0.3-0.7mmol/L) compared with conventional four-hour thrice-weekly HD treatment.
23
 In spite of the 
relatively low removal rates of phosphorus achieved by HD it is indicative that HD alone cannot 
correct the phosphate levels that are associated with the usual dietary content of phosphate.
21,22
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Therefore, successful treatment of hyperphosphatemia requires patients adhering to a combination of 
dietary phosphate restrictions,
8
 use of oral phosphate binder therapy to reduce intestinal phosphate 
absorption
21
 and adequate HD prescription to promote removal of phosphate.
24
  
Adherence to phosphate control 
Research on adherence to phosphate control dates back to 1960.
14
 However, the use of education 
and behavioral interventions to improve long term adherence to phosphate control has been 
subjected to less investigation in people with ESKD. Several research studies indicate education and 
behavioral interventions could help individuals change their behavior and hence increase adherence 
to phosphate control.
5,13,20,25,26
 A number of studies have used different educational interventions, 
carried out by either nurses or dieticians. The education sessions were one-on-one or group, and 
verbal or video was used to provide the education.
13,14,27,28
 Also, structured psychological approaches 
aimed at helping patients to change their beliefs, consequently developing healthy behavior, have 
been used to produce positive results in improving adherence to diet, medication and HD treatment.
28-
31
 These studies illustrate that theoretical and empirically based behavioral approaches are feasible 
and can result in a positive reduction of serum phosphate level. However, further developments of 
clinically useful behavioral and educational strategies are needed to sustain long term adherence with 
phosphate control. 
A literature search of the Cochrane central register of controlled trials, JBI, Prospero international 
prospective register of systematic review and Campbell collaboration systematic reviews was 
conducted and only one systematic review of relevance to this topic was found. This systematic 
review was of randomized controlled trials of educational and counselling interventions to improve 
dietary phosphate adherence in both HD and pre-dialysis patients.
26
 However, this systematic review 
did not include all treatment methods that are used in combination to control phosphate. 
The control of serum phosphate levels in people receiving HD continues to be a challenge for 
practitioners and is of clinical significance to patient outcomes. If left untreated hyperphosphatemia 
significantly increases the risk of morbidity and mortality in people with ESKD.
12
 It is important to 
review studies that have been undertaken comparing the outcomes of education and behavioral 
interventions, regardless of study design, targeting patient adherence to dietary phosphate intake, 
phosphate binder medication and HD treatment.  
Keywords 
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Inclusion criteria 
Types of participants 
This review will consider studies that include adults over the age of 18 years, with ESKD undergoing 
HD. In this review participants included will be attending dialysis facilities regardless of frequency and 
duration of treatment sessions per week. Studies with participants receiving hemodiafiltration will be 
excluded.  
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Types of intervention(s)/phenomena of interest 
This review will consider studies that evaluate educational and behavioral interventions that are 
designed to improve adherence to dietary phosphate restriction, phosphate binder medication and HD 
as compared to “routine care”; care without educational or behavioral interventions or any types of 
informal educational of phosphate control interventions which promote adherence. This will include 
studies that investigated different types of education or behavioral methods used alone or in a 
combination, either in routine or research intervention programs, regardless of how long the programs 
were and whether or not a follow-up was conducted. The intervention could be delivered by any 
health professional.  
Types of outcomes 
This review will consider studies that include the following outcome measures: 
Primary outcomes of interest are: (1) patient knowledge related to phosphate control as measured by 
self-report questionnaire, (2) patient adherence to phosphate control strategies as measured by tablet 
counts, electronic monitoring, patient self-report questionnaire, and/or health care professionals' 
reports, and (3) serum phosphate levels and calcium-phosphate product levels. 
Secondary outcomes include: (1) patient CKD self-management behavior related to phosphate 
control, and (2) patient perceived self-efficacy for CKD phosphate control, as measured by self-report 
questionnaires. 
Types of studies 
This review will consider both experimental and observational study designs including randomized 
controlled trials, non-randomized controlled trials, quasi-experimental, before and after studies, 
prospective, cross sectional studies and retrospective cohort studies that evaluate educational or 
behavioral interventions that improve adherence to phosphate control in adults receiving HD. 
Search strategy 
The search strategy aims to find both published and unpublished studies. A three-step search 
strategy will be utilized in this review. An initial limited search of MEDLINE and CINAHL will be 
undertaken followed by an analysis of the text words contained in the title and abstract, and of the 
index terms used to describe the article. A second search using all identified keywords and index 
terms will then be undertaken across all included databases. Third, the reference list of all identified 
reports and articles will be searched for additional studies. Studies published in the English language 
will be considered for inclusion in this review. To ensure the search is comprehensive and covers the 
most relevant recent published studies in this topic, studies from the last 10 years, thus 2005 to 2014, 
will be considered for inclusion in this review.  
The databases to be searched include: 
The Cochrane Central Register of Controlled Trials (CENTRAL); 
 MEDLINE  
 EMBASE  
 CINAHL 
PsycINFO  
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SCOPUS 
The search for unpublished studies will include: 
Web of Science and Digital Dissertations, conference proceedings and theses  
 
Initial keywords to be used will be: 
Kidney failure, end stage kidney disease, ESKD, end stage renal failure, ESRF, chronic kidney 
disease, CKD,  renal insufficiency, chronic renal failure (CRF) or chronic kidney failure (CKF) 
Kidney replacement therapy, KRT, renal replacement therapy, RRT, hemodialysis renal dialysis,  
Health education/program/programme, behavioural/behavioral therapy, cognitive therapy 
Knowledge, self-management, knowledge retention, health literacy, self-efficacy 
Phosphate control, diet therapy, phosphate controlling medication, phosphate binding medication, 
hyperphosphatemia, hyperphosphataemia 
Adherence, compliance, non-compliance, non adherence, non compliant   
Assessment of methodological quality 
Papers selected for retrieval will be assessed by two independent reviewers for methodological 
validity prior to inclusion in the review using standardized critical appraisal instruments from the 
Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI-
MAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through 
discussion or with a third reviewer. 
Data collection 
Data will be extracted from papers included in the review using the standardized data extraction tool 
from JBI-MAStARI (Appendix II). The data extracted will include specific details about the 
interventions, populations, study methods and outcomes of significance to the review question and 
specific objectives. 
Data synthesis 
Quantitative data will, where possible, be pooled in statistical meta-analysis using JBI-MAStARI. All 
results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) 
and weighted mean differences (for continuous data), and their 95% confidence intervals, will be 
calculated for analysis. Heterogeneity will be assessed statistically using the standard Chi-square and 
also explored using subgroup analyses based on the different study designs included in this review. 
Where statistical pooling is not possible the findings will be presented in narrative form including 
tables and figures to aid in data presentation where appropriate. 
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Appendix I: Appraisal instruments 
MAStARI appraisal instrument 
this isa test message 
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Appendix II: Data extraction instruments 
MAStARI data extraction instrument 
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